Vaxcyte surges on pneumococcal vaccine late-stage trial success

** Vaxcyte shares PCVX.O jump 26% to $71.17 premarket

** Vaxcyte says its 31-strain pneumonia vaccine, VAX-31, meets all main goals in a late-stage trial and generates immune responses comparable to or better than Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive

** The vaccine is as safe and well tolerated as the current vaccines

** Vaxcyte expects results from two more late-stage trials in H1 2027 and plans to apply for FDA approval in H1 2028

** As of last close, stock up 22.4% YTD